<DOC>
	<DOCNO>NCT00108498</DOCNO>
	<brief_summary>This study determine mirtazapine , unique antidepressant disturb sleep , improve obstructive sleep apnea ( OSA ) . The design randomize , crossover , double blind , placebo control . On two consecutive night one week , patient receive either 30 mg mirtazapine placebo bedtime . The following week , alternative medication administer . The patient know mild moderate sleep apnea . The endpoint study apnea + hypopnea index ( AHI ) , sleep quality , degree arterial oxygen desaturation .</brief_summary>
	<brief_title>New Pharmacological Treatment Obstructive Sleep Apnea</brief_title>
	<detailed_description />
	<mesh_term>Apnea</mesh_term>
	<mesh_term>Sleep Apnea Syndromes</mesh_term>
	<mesh_term>Sleep Apnea , Obstructive</mesh_term>
	<mesh_term>Mirtazapine</mesh_term>
	<criteria>Known OSA mild moderate On antidepressant antipsychotic medication</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>sleep apnea</keyword>
	<keyword>mirtazapine</keyword>
	<keyword>sleep</keyword>
</DOC>